Priority Review for Indivior's RBP-6000

Indivior plc (LSE:INDV) said FDA accepted and granted Priority Review to an NDA for RBP-6000 to treat adults with moderate to severe opioid use disorder. Its PDUFA date is Nov. 30. The product is under review as part of a complete treatment plan that includes counseling and psychosocial support.

The company said FDA will hold an advisory committee meeting to discuss the application, which will likely take place in 4Q17...